Ann Dermatol.  2013 Nov;25(4):504-505. 10.5021/ad.2013.25.4.504.

Cetuximab Related Eyelash Elongations for Patients with Metastatic Rectum Carcinoma: Metabolic Complete Response

Affiliations
  • 1Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey. yukselurun@gmail.com

Abstract

No abstract available.


MeSH Terms

Antibodies, Monoclonal, Humanized
Humans
Rectum*
Cetuximab
Antibodies, Monoclonal, Humanized

Figure

  • Fig. 1 Eyelash elongation after cetuximab treatment (published with permission of patient).

  • Fig. 2 Patient's second photograph after reintroduction of cetuximab (published with permission of patient).


Reference

1. Winder T, Lenz HJ. Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev. 2010; 36:550–556.
Article
2. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008; 19:508–515.
Article
3. Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol. 2010; 24:453–459.
Article
4. Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf. 2007; 6:175–182.
Article
5. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005; 16:1425–1433.
Article
Full Text Links
  • AD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr